29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria

Epidemiology & Etiologic Spectrum of Acute Pharyngitis

Acute pharyngitis is one of the most frequent chief complaints encountered in primary care, accounting for approximately 12 million ambulatory visits annually in the United States. Although pharyngitis prompts substantial patient anxiety regarding 'strep throat', the clinical reality is that the vast majority of acute sore throats across all age groups are caused by self-limited viral respiratory pathogens.

Epidemiological Distribution

• Children Aged 3 to 14 Years: Group A beta-hemolytic Streptococcus (Streptococcus pyogenes, GAS) accounts for 15% to 30% of acute pharyngitis cases. This represents the peak epidemiological demographic for streptococcal disease.
• Adults (>=15 Years): GAS accounts for only 5% to 15% of adult pharyngitis presentations; more than 85% to 90% of adult sore throats are viral.
• Children Younger Than 3 Years: GAS pharyngitis is distinctly uncommon (<5%), and when present, manifests atypical symptoms ('streptococcosis': chronic mucopurulent rhinorrhea, low-grade fever, excoriated nares, and generalized adenopathy). Because Acute Rheumatic Fever is virtually unheard of in children under 3 years of age, diagnostic testing for GAS is strictly not indicated in this age group unless a household sibling has confirmed GAS.

                  ETIOLOGY OF ACUTE PHARYNGITIS BY AGE

      Children (3-14 Years)                       Adults (>=15 Years)
   ┌───────────────────────────┐               ┌───────────────────────────┐
   │  Viral (~70-85%)          │               │  Viral (>85-90%)          │
   │  • Rhinovirus, Adeno,     │               │  • Rhinovirus, Corona,    │
   │    Entero, EBV, Parainfl. │               │    Adeno, Influenza, EBV  │
   ├───────────────────────────┤               ├───────────────────────────┤
   │  GAS / S. pyogenes        │               │  GAS / S. pyogenes        │
   │  (15% to 30%)             │               │  (5% to 15%)              │
   ├───────────────────────────┤               ├───────────────────────────┤
   │  Other Bacteria (<5%)     │               │  Other Bacteria (<5%)     │
   │  • Groups C/G Strep       │               │  • F. necrophorum, C/G,   │
   │  • M. pneumoniae          │               │    N. gonorrhoeae         │
   └───────────────────────────┘               └───────────────────────────┘

Viral Etiologies & The Clinical 'Viral Signature'

In viral pharyngitis, inflammatory damage to the pharyngeal mucosa is mediated by viral replication and cytotoxic cytokine release. Specific viral pathogens produce distinctive physical examination findings:

1. Rhinovirus and Coronavirus: Mild pharyngeal erythema accompanied by prominent sneezing, clear rhinorrhea, and nasal congestion.
2. Adenovirus: Causes pharyngoconjunctival fever, marked by prominent pharyngitis, high fevers, follicular non-purulent conjunctivitis, and preauricular lymphadenopathy.
3. Enteroviruses (Coxsackievirus A): Produces herpangina—abrupt onset of high fever, sore throat, and classic 1- to 2-mm grayish-white papulovesicular lesions that rupture into shallow, painful ulcers with erythematous halos localized to the soft palate, uvula, and anterior tonsillar pillars (the posterior pharynx and gingiva are spared). Also causes Hand-Foot-and-Mouth disease.
4. Epstein-Barr Virus (EBV): The primary agent of infectious mononucleosis, characterized by profound tonsillar enlargement covered by shaggy white-gray exudates, palatal petechiae, fever, symmetric posterior cervical lymphadenopathy, and splenomegaly.
5. Herpes Simplex Virus (HSV-1): Primary gingivostomatitis presenting with friable, bleeding gums and vesicular ulcerations involving the anterior oral cavity, hard palate, and lips.
6. Acute Retroviral Syndrome (Primary HIV): Manifests 2 to 4 weeks post-exposure as a mononucleosis-like illness with pharyngeal erythema (often non-exudative), shallow painful mucocutaneous ulcerations, generalized non-tender lymphadenopathy, fever, arthralgias, and a non-pruritic maculopapular rash on the trunk.

[!TIP] The 'Viral Signature' Rule: The presence of cough, rhinorrhea/coryza, hoarseness, conjunctivitis, anterior oral mucosal ulcerations, or diarrhea points strongly to a viral upper respiratory infection. If these viral features are prominent, diagnostic testing for GAS (RADT or throat culture) should be withheld, as positive tests in this setting merely capture chronic asymptomatic streptococcal carriage.

Bacterial Pathogens Beyond Group A Streptococcus

• Group C and Group G Streptococci: Large-colony beta-hemolytic streptococci that cause acute exudative pharyngitis clinically indistinguishable from GAS, frequently occurring in foodborne outbreaks or among college students. Crucially, Groups C and G do NOT cause Acute Rheumatic Fever, although they can trigger post-streptococcal glomerulonephritis.
• Fusobacterium necrophorum: Anaerobic, pleomorphic Gram-negative rod increasingly recognized as an important cause of endemic pharyngitis in adolescents and young adults (ages 15 to 24). It is the primary etiologic agent of Lemierre syndrome (internal jugular vein septic thrombophlebitis).
• Arcanobacterium haemolyticum: Gram-positive bacillus causing acute exudative pharyngitis in adolescents and young adults, accompanied by a scarlatiniform, fine maculopapular rash on the extensor surfaces of limbs that spares the face. Intrinsically resistant to penicillins; requires treatment with oral macrolides.
• Neisseria gonorrhoeae: Gram-negative diplococcus acquired via orogenital contact; causes asymptomatic infection or severe pharyngeal erythema with cervical lymphadenopathy. Requires nucleic acid amplification testing (NAAT) or specialized Thayer-Martin culture; treated with intramuscular ceftriaxone.
• Corynebacterium diphtheriae: Rare in vaccinated populations; produces a dense, tenacious, gray-black pseudomembrane firmly adherent to the tonsils, uvula, and soft palate that bleeds profusely on attempted dislodgement, accompanied by profound cervical soft tissue edema ('bull neck') and systemic toxin-mediated myocarditis and neuropathies.

---

The Modified Centor Criteria (McIsaac Score): Risk Stratification

Because clinical impression alone reliably overestimates the likelihood of streptococcal pharyngitis (clinicians prescribe antibiotics in >60% of pharyngitis visits despite a GAS prevalence of 10%), validated clinical decision rules are essential. The Centor criteria, initially formulated in emergency department adults, were modified by McIsaac to incorporate age adjustments, establishing the standard Modified Centor (McIsaac) score:

                  MODIFIED CENTOR (McISAAC) SCORE

   CLINICAL CRITERIA                                           POINTS
   ──────────────────────────────────────────────────────────────────
   1. History of documented fever (>38.0°C or 100.4°F)          +1
   2. Absence of cough                                          +1
   3. Tender anterior cervical lymphadenopathy                  +1
   4. Tonsillar swelling or tonsillar exudates                  +1
   ──────────────────────────────────────────────────────────────────
   AGE ADJUSTMENT
   • Age 3 to 14 years                                          +1
   • Age 15 to 44 years                                          0
   • Age >=45 years                                             -1
   ──────────────────────────────────────────────────────────────────
   TOTAL POSSIBLE SCORE: -1 to 5 points

Evidence-Based Risk Stratification and Clinical Action

---

Diagnostic Testing Protocol: RADT & The Pediatric vs. Adult Divergence

To ensure rational antibiotic prescribing, clinical criteria must be coupled with point-of-care microbiological verification.

               DIAGNOSTIC ALGORITHM FOR SUSPECTED GAS

                      Modified Centor Score >=2
                                 │
                                 ▼
                    Perform Throat Swab for RADT
                    (Vigorous Swab of Both Tonsils/Pillars)
                                 │
                 ┌───────────────┴───────────────┐
                 ▼                               ▼
           RADT POSITIVE                   RADT NEGATIVE
                 │                               │
                 ▼                               ▼
          INITIATE ANTIBIOTICS             Patient Age?
          • Oral Penicillin V             ┌──────┴──────┐
          • Oral Amoxicillin              ▼             ▼
          • Cephalexin (if allergic)   Child <18y    Adult >=18y
                                          │             │
                                          ▼             ▼
                                   MANDATORY BACKUP   NO BACKUP
                                    THROAT CULTURE     CULTURE
                                          │             │
                                    Wait 48h; treat   Symptomatic
                                    only if positive    Care Only

Rapid Antigen Detection Testing (RADT)

• Mechanism: Utilizes enzymatic or acid extraction to isolate the Lancefield group A carbohydrate antigen from throat swabs, detected via sandwich immunoassay.
• Performance: High specificity (>=95% to 98%), with moderate-to-high sensitivity (70% to 90%).
• Swabbing Technique: The sterile Dacron or Rayon swab must vigorously sample both palatine tonsils (or tonsillar fossae) and the posterior pharyngeal wall, specifically swabbing areas of purulence or ulceration. Contact with the tongue, uvula, buccal mucosa, or lips must be avoided to prevent saliva contamination and false negatives.

The Critical Board Divergence: Backup Throat Cultures

• Pediatric Patients and Adolescents (<18 Years): A negative RADT MUST be reflexively followed by a backup throat culture (inoculated onto 5% sheep blood agar). Rationale: Because the sensitivity of point-of-care RADT is imperfect (~70-90%), up to 10% to 30% of true GAS cases could be missed. In children, untreated GAS carries a tangible risk of triggering Acute Rheumatic Fever (ARF). A backup throat culture ensures that false-negative RADTs are detected and treated within the 9-day therapeutic window for ARF prevention.
• Adult Patients (>=18 Years): A negative RADT does NOT require a backup throat culture. Rationale: The incidence of Acute Rheumatic Fever in adults in developed nations is virtually zero (<1 case per million). Furthermore, throat cultures in adults frequently identify low-inoculum asymptomatic GAS carriage (which affects 5% to 10% of the healthy adult population), resulting in unnecessary antibiotic exposure. A negative RADT in an adult rules out GAS for clinical purposes.

---

Evidence-Based Antimicrobial Therapy for GAS Pharyngitis

Therapeutic Objectives

Antimicrobial treatment of confirmed GAS pharyngitis is directed toward four distinct clinical goals:

1. Prevention of Acute Rheumatic Fever: The paramount public health objective. Complete prevention is achieved as long as antibiotics are initiated within 9 days of symptom onset.
2. Shortening Symptom Duration: Hastens clinical resolution of fever, throat pain, and dysphagia by approximately 1 to 2 days compared to placebo.
3. Prevention of Suppurative Complications: Dramatically reduces the incidence of peritonsillar abscess, retropharyngeal abscess, suppurative cervical lymphadenitis, sinusitis, and otitis media.
4. Interruption of Transmission: Eradicates viable GAS from the pharynx within 24 hours. Patients are considered non-contagious and may return to school or work after 24 hours of effective antibiotic therapy provided they are afebrile.

First-Line Antimicrobial Regimens

Streptococcus pyogenes has maintained 100% universal susceptibility to beta-lactam antibiotics; clinical penicillin resistance has never been documented anywhere in the world.

                  GAS ANTIMICROBIAL DOSING PROTOCOLS

   ORAL PENICILLIN V (Gold Standard)
   • Adults: 500 mg PO BID or TID for 10 days
   • Children: 250 mg PO BID or TID for 10 days
   
   ORAL AMOXICILLIN (Pediatric Preferred - Palatable Suspension)
   • Adults: 500 mg PO BID or 1,000 mg PO once daily for 10 days
   • Children: 50 mg/kg PO once daily (max 1,000 mg) for 10 days
   
   INTRAMUSCULAR BENZATHINE PENICILLIN G (Single Injection)
   • Weight >=27 kg / Adults: 1,200,000 units IM single dose
   • Weight <27 kg: 600,000 units IM single dose
   • Ideal for non-compliance, emesis, or personal/family history of ARF

Management of the Penicillin-Allergic Patient

Antimicrobial choice depends strictly on whether the allergy was a non-severe cutaneous reaction or a severe, life-threatening IgE-mediated anaphylactic reaction:

1. Non-Anaphylactic / Non-IgE Allergy (e.g., mild maculopapular rash without hives or systemic symptoms):
   • First-Generation Cephalosporin: Cephalexin 20 mg/kg/dose PO BID (max 500 mg BID) for 10 days, or Cefadroxil 30 mg/kg once daily (max 1,000 mg) for 10 days.
   • Cross-reactivity between penicillins and first-generation cephalosporins is extremely low (<1% to 2% in modern formulations lacking ampicillin side-chain similarities), making cephalexin highly effective, safe, and bactericidal.
2. Severe IgE-Mediated Allergy (Anaphylaxis, Angioedema, Bronchospasm, Immediate Urticaria):
   • All beta-lactams (including all cephalosporins) are strictly contraindicated.
   • Azithromycin: 12 mg/kg PO once daily (max 500 mg) on day 1, followed by 6 mg/kg once daily (max 250 mg) on days 2 through 5 (5-day course).
   • Clarithromycin: 15 mg/kg/day PO divided BID (max 250 mg BID) for 10 days.
   • Clindamycin: 20 mg/kg/day PO divided TID (max 300 mg TID) for 10 days. Clindamycin is particularly useful in recurrent GAS or carriage states due to excellent tissue penetration and inhibition of streptococcal pyrogenic exotoxin synthesis.
   • Caveat on Macrolides: Approximately 5% to 15% of GAS isolates in the United States exhibit macrolide resistance mediated by erm or mef genes; macrolides must be reserved strictly for severe beta-lactam allergies.

---

Non-Suppurative Post-Streptococcal Sequelae: ARF vs. PSGN

The two major non-suppurative immunological complications of Streptococcus pyogenes infection represent a cornerstone topic on board examinations. Differentiating their pathophysiology, latency, clinical presentation, and preventive potential is critical:

             NON-SUPPURATIVE SEQUELAE: THE CRUCIAL CONTRAST

   ACUTE RHEUMATIC FEVER (ARF)        POST-STREP GLOMERULONEPHRITIS (PSGN)
   ───────────────────────────        ────────────────────────────────────
   • Type II Hypersensitivity         • Type III Hypersensitivity
   • Molecular Mimicry (M-Protein)    • Immune Complex Deposition (Subepi)
   • Latency: 2 to 4 Weeks            • Latency: 1-3 Wks (Pharynx) / 3-6 Wks (Skin)
   • Follows PHARYNGITIS ONLY         • Follows PHARYNGITIS OR IMPETIGO
   • Mitral Regurg, Polyarthritis     • Cola Urine, Edema, HTN (Nephritic)
   • Low C3 NOT typical               • Marked Hypocomplementemia (Low C3)
   • PREVENTED BY ANTIBIOTICS!        • NOT PREVENTED BY ANTIBIOTICS!
     (Within 9 days of onset)           (Antibiotics do NOT stop PSGN)

Acute Rheumatic Fever (ARF) & The Revised Jones Criteria

• Pathogenesis: A systemic autoimmune disease provoked by an aberrant host immune response. Antibodies directed against the hypervariable M-protein of rheumatogenic GAS strains cross-react with human tissue antigens (molecular mimicry)—specifically cardiac myosin, valve laminin, synovial antigens, and basal ganglia neuronal surface gangliosides.
• Clinical Latency: Manifests 2 to 4 weeks following an untreated episode of GAS pharyngitis. ARF never follows streptococcal skin infections (impetigo).
• The Revised Jones Criteria: Confirmation requires proof of preceding GAS infection (positive RADT, positive throat culture, or rising anti-streptolysin O [ASO] / anti-DNase B titers) PLUS either 2 Major Criteria OR 1 Major + 2 Minor Criteria:

                      REVISED JONES CRITERIA (ARF)

   MAJOR CRITERIA (JONES)              MINOR CRITERIA (FEVER)
   ────────────────────────────────    ──────────────────────────────
   J - Joints: Migratory Polyarthritis F - Fever (>=38.5°C)
       (Large joints; highly NSAID-     E - ECG: Prolonged PR Interval
       responsive)                         (Adjusted for age)
   O - Carditis ('O' resembles heart)  V - Valvulitis markers (elevated
       (Pancarditis; mitral valve          ESR >=60 mm/h or CRP >=3.0)
       regurgitation most common)      E - Elevated acute phase reactants
   N - Nodules (Subcutaneous)          R - Redness/Pain: Arthralgia
       (Firm, painless, extensor)          (Cannot use if arthritis is Major)
   E - Erythema Marginatum
       (Serpiginous, pink borders,
       central clearing; non-pruritic)
   S - Sydenham Chorea (St. Vitus)
       (Rapid, involuntary movements,
       facial grimacing, lability)

• Secondary Prophylaxis: Patients with confirmed ARF require long-term secondary antimicrobial prophylaxis to prevent recurrent attacks and worsening rheumatic heart disease. The preferred regimen is intramuscular Benzathine Penicillin G 1.2 million units every 3 to 4 weeks. Duration ranges from 5 years (for ARF without carditis) up to 10 years or until age 21 to 40 (for ARF with residual valvular heart disease).

Post-Streptococcal Glomerulonephritis (PSGN)

• Pathogenesis: An immune-complex-mediated (Type III) glomerulonephritis triggered by 'nephritogenic' strains of GAS bearing specific surface antigens (streptococcal pyrogenic exotoxin B [SPE B] or nephritis-associated plasmin receptor [NAPIr]). Circulating antigen-antibody complexes deposit within the glomerular basement membrane, producing subepithelial electron-dense 'humps', complement activation, and neutrophil infiltration.
• Clinical Latency: Occurs 1 to 3 weeks following streptococcal pharyngitis, OR 3 to 6 weeks following streptococcal pyoderma / impetigo.
• Clinical Manifestations: Classic acute nephritic syndrome:
  1. Gross Hematuria: Dark, smoky, 'tea-colored' or 'coca-cola-colored' urine with dysmorphic red blood cells and red blood cell casts;
  2. Edema: Characteristically periorbital edema prominent upon awakening, progressing to peripheral dependent edema;
  3. Hypertension: Mild to moderate volume-overload arterial hypertension;
  4. Oliguria & Proteinuria: Sub-nephrotic range proteinuria (<3.5 g/day).
• Diagnostic Laboratory Findings: Profound hypocomplementemia with depressed serum C3 and normal or mildly reduced C4 (reflecting alternate complement pathway consumption; C3 normalizes within 6 to 8 weeks). Elevated ASO (post-pharyngitis) and anti-DNase B (post-impetigo).
• CRITICAL BOARD FACT: Antibiotic treatment of the initial streptococcal pharyngitis or impetigo DOES NOT PREVENT the development of Post-Streptococcal Glomerulonephritis! (Antibiotics reduce organism spread to close contacts, but immune complexes have already formed or are destined to form). Management is purely supportive: dietary sodium and fluid restriction, loop diuretics (furosemide) for volume overload, and calcium channel blockers for hypertension. Prognosis in pediatric patients is outstanding (>95% achieve complete recovery without residual renal impairment).

---

Suppurative Complications & Urgent Differentials

Peritonsillar Abscess (Quinsy)

• Pathology: A localized collection of pus in the potential space between the fibrous capsule of the palatine tonsil and the superior pharyngeal constrictor muscle. Typically polymicrobial, involving GAS, S. aureus, and oral anaerobes (Fusobacterium, Prevotella).
• Clinical Triad: (1) Severe, progressive unilateral sore throat and odynophagia, (2) Trismus (inability to open the mouth due to inflammatory spasm of the internal pterygoid muscle), and (3) A muffled, guttural 'hot potato' voice.
• Physical Examination: Marked unilateral swelling displacing the affected tonsil inferomedially, fullness and erythema of the ipsilateral anterior tonsillar pillar and soft palate, and deviation of the uvula toward the contralateral (unaffected) side. Ipsilateral referred otalgia and drooling are common.
• Management: Emergent needle aspiration or surgical incision and drainage (I&D) performed under local anesthesia. Followed by broad-spectrum parenteral or oral antimicrobial therapy covering GAS and anaerobes (amoxicillin-clavulanate 875/125 mg PO BID or clindamycin 300 mg PO TID for 14 days), alongside a single dose of systemic dexamethasone (10 mg IV/PO) to accelerate pain relief and resolve trismus.

Infectious Mononucleosis (EBV)

• Etiology: Primary infection with Epstein-Barr virus (human herpesvirus 4).
• Clinical Tetrad: Fever, severe exudative pharyngitis (with dense, confluent white-gray exudates), prominent symmetric posterior cervical and occipital lymphadenopathy, and profound fatigue. Splenomegaly is palpable in 50% to 60% of cases; hepatomegaly and palatal petechiae may be present.
• Laboratory Evaluation: Peripheral blood smear reveals absolute lymphocytosis (>50% of white blood cells) with >10% atypical lymphocytes (reactive CD8+ cytotoxic T cells). Point-of-care heterophile antibody test (Monospot) is positive by week 2 of illness (may be falsely negative in the first week or in children <4 years; confirm with EBV-specific viral capsid antigen [VCA] IgM/IgG if suspicion is high).
• The Aminopenicillin Rash: If an adolescent or young adult with acute EBV mononucleosis is mistakenly diagnosed with bacterial pharyngitis and prescribed amoxicillin or ampicillin, up to 70% to 90% develop a diffuse, copper-colored, pruritic maculopapular morbilliform rash 5 to 7 days into the antibiotic course. This is an immune-complex-mediated non-allergic drug eruption, NOT a true IgE-mediated penicillin allergy, and does not preclude future beta-lactam use.
• Management: Supportive care (hydration, NSAIDs). Corticosteroids are reserved solely for impending upper airway obstruction from massive tonsillar hypertrophy or severe thrombocytopenia/hemolytic anemia. Strict avoidance of all contact sports and heavy lifting for at least 3 to 4 weeks from symptom onset is mandatory to prevent catastrophic traumatic splenic rupture.

Lemierre Syndrome (Post-Anginal Septicemia)

• Pathogen: Fusobacterium necrophorum.
• Pathogenesis: Begins as acute exudative pharyngitis in an otherwise healthy young adult, which invades the lateral pharyngeal space to cause septic thrombophlebitis of the internal jugular vein (IJV), followed by hematogenous dissemination of septic emboli.
• Clinical Presentation: High spiking fevers, rigors, unilateral tenderness and induration along the anterior border of the sternocleidomastoid muscle, and pleuritic chest pain with hemoptysis from cavitary septic pulmonary emboli.
• Diagnosis & Treatment: Contrast-enhanced CT of the neck (demonstrating filling defects within the thrombosed internal jugular vein) and chest CT (multiple peripheral nodular cavitary infiltrates). Blood cultures confirm F. necrophorum. Requires prolonged intravenous antibiotic therapy with ampicillin-sulbactam (3 g IV q6h) or ceftriaxone plus metronidazole for 3 to 6 weeks.

---

High-Yield Board Pearls: Acute Pharyngitis

• No Cough Rule: If an adult presents with a severe sore throat and fever, but has a persistent productive cough and runny nose, their Modified Centor score is <=1. Do NOT test for GAS and do NOT prescribe antibiotics.
• Universal Susceptibility: Streptococcus pyogenes has never developed resistance to penicillin. Treatment failures are almost always due to non-adherence to the 10-day oral regimen, recurrent re-exposure, or co-colonization with beta-lactamase-producing flora.
• The 9-Day Window: Antibiotics can be initiated up to 9 days after the onset of pharyngeal symptoms and still achieve full prevention of Acute Rheumatic Fever. There is no rush to treat empirically while awaiting backup throat culture results.
• PSGN is NOT Preventable: Always remember that antibiotics do NOT prevent post-streptococcal glomerulonephritis. A patient who receives appropriate penicillin for strep throat can still present 2 weeks later with gross hematuria and hypertension.
• EBV Rash Reassurance: The amoxicillin-induced rash in infectious mononucleosis does not represent a life-long drug allergy. Do not label the patient as 'penicillin-allergic' in their medical record without confirmatory testing.
• Trismus Means Abscess: Severe sore throat accompanied by inability to fully open the jaw (trismus) and contralateral uvular deviation is a peritonsillar abscess until proven otherwise, mandating drainage.